Name:
Flunitrazepam
Type:
Benzodiazepine
AKA:
Rohypnol, Narcozep, Darkene, Roipnol
Flunitrazepam image
Synthetic substance, no natural derivative
IUPAC Logo
Flunitrazepam image
Flunitrazepam, marketed under the brand name Rohypnol, is a benzodiazepine developed in the 1970s. It is used medically for its sedative, hypnotic, and anxiolytic properties. Flunitrazepam gained notoriety in the 1990s as a 'date rape' drug due to its powerful sedative effects and amnesic properties. Its legal status varies, with strict regulations in many countries to prevent misuse.
Synthetic Substances Image
Flunitrazepam, a benzodiazepine, is used for its sedative and anxiolytic effects. As a downer, it induces significant drowsiness and muscle relaxation. Short-term effects include reduced anxiety and sedation, while long-term use can lead to dependence and cognitive impairment. Overdose risks include severe sedation and respiratory depression. Safe dosing typically ranges from 1-2 mg. Recent research emphasizes its effectiveness in treating insomnia but also notes the risks of misuse and dependence.
N/A
Flunitrazepam, a benzodiazepine, affects GABA-A receptors, leading to anxiolytic and sedative effects. Psychological impacts include reduced anxiety and impaired cognition. Long-term use can cause dependence and cognitive issues. Recent studies examine its efficacy in treating insomnia and anxiety disorders, along with cognitive side effects.
N/A
Flunitrazepam, commonly known as Rohypnol, is a benzodiazepine that has gained notoriety for its use as a 'date rape drug' due to its potent sedative and amnesic effects. Its cultural significance is marked by its association with criminal activity and its portrayal in media as a dangerous and illicit substance. Despite its medical use for treating severe insomnia and as a pre-anesthetic, the negative connotations surrounding its misuse have led to strict regulations and its ban in many countries. Flunitrazepam's role in the cultural narrative is one of caution and highlights the dark side of drug misuse.
N/A